Literature DB >> 19103595

Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform.

Jiyoung Y Cha1, Savitri Maddileti, Natalia Mitin, T Kendall Harden, Channing J Der.   

Abstract

Alternative splice variants of fibroblast growth factor receptor 2 (FGFR2) IIIb, designated C1, C2, and C3, possess progressive reduction in their cytoplasmic carboxyl termini (822, 788, and 769 residues, respectively), with preferential expression of the C2 and C3 isoforms in human cancers. We determined that the progressive deletion of carboxyl-terminal sequences correlated with increasing transforming potency. The highly transforming C3 variant lacks five tyrosine residues present in C1, and we determined that the loss of Tyr-770 alone enhanced FGFR2 IIIb C1 transforming activity. Because Tyr-770 may compose a putative YXXL sorting motif, we hypothesized that loss of Tyr-770 in the 770YXXL motif may cause disruption of FGFR2 IIIb C1 internalization and enhance transforming activity. Surprisingly, we found that mutation of Leu-773 but not Tyr-770 impaired receptor internalization and increased receptor stability and activation. Interestingly, concurrent mutations of Tyr-770 and Leu-773 caused 2-fold higher transforming activity than caused by the Y770F or L773A single mutations, suggesting loss of Tyr and Leu residues of the 770YXXL773 motif enhances FGFR2 IIIb transforming activity by distinct mechanisms. We also determined that loss of Tyr-770 caused persistent activation of FRS2 by enhancing FRS2 binding to FGFR2 IIIb. Furthermore, we found that FRS2 binding to FGFR2 IIIb is required for increased FRS2 tyrosine phosphorylation and enhanced transforming activity by Y770F mutation. Our data support a dual mechanism where deletion of the 770YXXL773 motif promotes FGFR2 IIIb C3 transforming activity by causing aberrant receptor recycling and stability and persistent FRS2-dependent signaling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103595      PMCID: PMC2649112          DOI: 10.1074/jbc.M803998200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins.

Authors:  S H Ong; Y R Hadari; N Gotoh; G R Guy; J Schlessinger; I Lax
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Signals for sorting of transmembrane proteins to endosomes and lysosomes.

Authors:  Juan S Bonifacino; Linton M Traub
Journal:  Annu Rev Biochem       Date:  2003-03-06       Impact factor: 23.643

Review 3.  Defective downregulation of receptor tyrosine kinases in cancer.

Authors:  Kristi G Bache; Thomas Slagsvold; Harald Stenmark
Journal:  EMBO J       Date:  2004-07-01       Impact factor: 11.598

Review 4.  Evolution of the Fgf and Fgfr gene families.

Authors:  Nobuyuki Itoh; David M Ornitz
Journal:  Trends Genet       Date:  2004-11       Impact factor: 11.639

Review 5.  Negative receptor signalling.

Authors:  Ivan Dikic; Silvia Giordano
Journal:  Curr Opin Cell Biol       Date:  2003-04       Impact factor: 8.382

6.  The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors.

Authors:  Irit Lax; Andy Wong; Betty Lamothe; Arnold Lee; Adam Frost; Jessica Hawes; Joseph Schlessinger
Journal:  Mol Cell       Date:  2002-10       Impact factor: 17.970

7.  Purification and characterization of a newly identified growth factor specific for epithelial cells.

Authors:  J S Rubin; H Osada; P W Finch; W G Taylor; S Rudikoff; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

8.  Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth.

Authors:  P W Finch; J S Rubin; T Miki; D Ron; S A Aaronson
Journal:  Science       Date:  1989-08-18       Impact factor: 47.728

9.  Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop.

Authors:  T Miki; T P Fleming; D P Bottaro; J S Rubin; D Ron; S A Aaronson
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

10.  Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.

Authors:  Jiyoung Y Cha; Que T Lambert; Gary W Reuther; Channing J Der
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

View more
  28 in total

1.  Tricyclic antidepressant amitriptyline activates fibroblast growth factor receptor signaling in glial cells: involvement in glial cell line-derived neurotrophic factor production.

Authors:  Kazue Hisaoka; Mami Tsuchioka; Ryoya Yano; Natsuko Maeda; Naoto Kajitani; Norimitsu Morioka; Yoshihiro Nakata; Minoru Takebayashi
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

2.  Mechanism of phosphorylation-induced activation of phospholipase C-gamma isozymes.

Authors:  Aurelie Gresset; Stephanie N Hicks; T Kendall Harden; John Sondek
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

3.  Competition between Grb2 and Plcγ1 for FGFR2 regulates basal phospholipase activity and invasion.

Authors:  Zahra Timsah; Zamal Ahmed; Chi-Chuan Lin; Fernando A Melo; Loren J Stagg; Paul G Leonard; Prince Jeyabal; Jonathan Berrout; Roger G O'Neil; Mikhail Bogdanov; John E Ladbury
Journal:  Nat Struct Mol Biol       Date:  2014-01-19       Impact factor: 15.369

Review 4.  Roles of FGFR in oral carcinogenesis.

Authors:  Xiaoyan Xie; Zhiyong Wang; Fangman Chen; Yao Yuan; Jiayi Wang; Rui Liu; Qianming Chen
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

Review 5.  Fibroblast growth factor signalling in osteoarthritis and cartilage repair.

Authors:  Yangli Xie; Allen Zinkle; Lin Chen; Moosa Mohammadi
Journal:  Nat Rev Rheumatol       Date:  2020-08-17       Impact factor: 20.543

6.  FGFR2 mutation in a Chinese family with unusual Crouzon syndrome.

Authors:  Zi-Li Li; Xue Chen; Wen-Juan Zhuang; Wei Zhao; Ya-Ni Liu; Fang-Xia Zhang; Ruo-Shui Ha; Jin-Hua Wu; Chen Zhao; Xun-Lun Sheng
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

Review 7.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

8.  PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Authors:  Ilaria Plantamura; Patrizia Casalini; Erica Dugnani; Marianna Sasso; Elvira D'Ippolito; Monica Tortoreto; Matilde Cacciatore; Carla Guarnotta; Cristina Ghirelli; Isabella Barajon; Francesca Bianchi; Tiziana Triulzi; Roberto Agresti; Andrea Balsari; Manuela Campiglio; Claudio Tripodo; Marilena V Iorio; Elda Tagliabue
Journal:  Mol Oncol       Date:  2014-03-27       Impact factor: 6.603

9.  The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer.

Authors:  X Mao; C Gauche; M W H Coughtrie; C Bui; S Gulberti; F Merhi-Soussi; N Ramalanjaona; I Bertin-Jung; A Diot; D Dumas; N De Freitas Caires; A M Thompson; J-C Bourdon; M Ouzzine; S Fournel-Gigleux
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

10.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Authors:  Alex Pearson; Elizabeth Smyth; Irina S Babina; Maria Teresa Herrera-Abreu; Noelia Tarazona; Clare Peckitt; Elaine Kilgour; Neil R Smith; Catherine Geh; Claire Rooney; Ros Cutts; James Campbell; Jian Ning; Kerry Fenwick; Amanda Swain; Gina Brown; Sue Chua; Anne Thomas; Stephen R D Johnston; Mazhar Ajaz; Katherine Sumpter; Angela Gillbanks; David Watkins; Ian Chau; Sanjay Popat; David Cunningham; Nicholas C Turner
Journal:  Cancer Discov       Date:  2016-05-13       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.